InsiderSignal.AI

InsiderSignal.ai

LPCN - Lipocine Inc.

Insider Purchase by Patel Mahesh V. (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Patel Mahesh V., serving as CEO at Lipocine Inc. (LPCN), purchased 25,000 shares at $2.03 per share, for a total transaction value of $50,750.00. Following this transaction, Patel Mahesh V. now holds 160,679 shares of LPCN.

This purchase represents a 18.00% increase in Patel Mahesh V.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, April 6, 2026 and publicly disclosed via SEC Form 4 filing on Monday, April 6, 2026, meaning the disclosure happened on the same day as the trade.

Lipocine Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Patel Mahesh V.

Patel Mahesh V.

CEO

Mahesh V. Patel, Ph.D. is the co-founder, Chairman, President, and Chief Executive Officer of Lipocine Inc. (LPCN), a biopharmaceutical company focused on drug delivery technologies.[[1]](https://biography.omicsonline.org/united-states-of-america/lipocine-inc/mahesh-v-patel-phd-895860)[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lpcn/lipocine/management)[[3]](https://www.lipocine.com/lipocine-management/) He has held these leadership roles since co-founding the company in 1997, with a tenure exceeding 29 years as of recent records, during which he also serves as Interim Principal Financial Officer.[[1]](https://biography.omicsonline.org/united-states-of-america/lipocine-inc/mahesh-v-patel-phd-895860)[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lpcn/lipocine/management) Dr. Patel brings over 20-25 years of experience in drug discovery support, drug delivery, and product development, including prior leadership in drug delivery R&D at Pharmacia and Upjohn in Kalamazoo, MI.[[1]](https://biography.omicsonline.org/united-states-of-america/lipocine-inc/mahesh-v-patel-phd-895860)[[3]](https://www.lipocine.com/lipocine-management/)[[5]](https://www.twst.com/interview/Interview-with-the-Chairman-President-and-CEO-Lipocine-Inc-NASDAQ-LPCN/) His expertise spans strategic planning, technology assessment, technical management, and product R&D.[[1]](https://biography.omicsonline.org/united-states-of-america/lipocine-inc/mahesh-v-patel-phd-895860)[[3]](https://www.lipocine.com/lipocine-management/) He holds a B.Pharm from Karnataka University in India, an M.S. in Physical Pharmacy from the University of Cincinnati, and a Ph.D. in Pharmaceutics from the University of Utah.[[1]](https://biography.omicsonline.org/united-states-of-america/lipocine-inc/mahesh-v-patel-phd-895860)[[3]](https://www.lipocine.com/lipocine-management/) As CEO, his total compensation is approximately $761,800 annually, and he owns about 1.96% of Lipocine’s shares, valued at around $1.1 million.[[2]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lpcn/lipocine/management)

View full insider profile →

Trade Price

$2.03

Quantity

25,000

Total Value

$50,750.00

Shares Owned

160,679

Trade Date

Monday, April 6, 2026

1 days ago

SEC Filing Date

Monday, April 6, 2026

HEALTHCAREBIOTECHNOLOGY

About Lipocine Inc.

Company Overview

No company information available
View news mentioning LPCN

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5422851

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime